Back to Search
Start Over
Carfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I Trial.
- Source :
- Clinical cancer research, 25 (14
- Publication Year :
- 2019
-
Abstract
- Carfilzomib is a novel generation proteasome inhibitor. The Carmysap trial demonstrated that twice-weekly KMP (carfilzomib, melphalan, prednisone) might challenge the MPV (melphalan, prednisone, bortezomib) standard. We sought to study KMP weekly, allowing to increase carfilzomib's dose with maintained efficacy and improved safety profile.<br />SCOPUS: ar.j<br />info:eu-repo/semantics/published
Details
- Database :
- OAIster
- Journal :
- Clinical cancer research, 25 (14
- Notes :
- 1 full-text file(s): application/pdf, English
- Publication Type :
- Electronic Resource
- Accession number :
- edsoai.on1192456022
- Document Type :
- Electronic Resource